Torsten Rüdiger Goesch
Chairman bei BIOSERGEN AB
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Viktor Drvota | M | 59 |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.
Dilafor AB
 Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | 8 Jahre |
| Peder Andersen | M | 72 |
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | 15 Jahre |
| Ellen Donnelly | M | 50 |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | 8 Jahre |
| John Öhd | M | 53 |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | 6 Jahre |
| Florian Schönharting | M | 55 | 19 Jahre | |
| Erik Yngve Holmer | M | 76 |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | 21 Jahre |
| Gunvor Ester Ekman-Ordeberg | M | 80 |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | 21 Jahre |
| Michael Forer | M | 58 |
Rosetta Capital Ltd.
 Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London.
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | 23 Jahre |
| Claus Bo Svendsen | M | 48 | 9 Jahre | |
| Lena Birgitta Degling Wikingsson | M | 61 |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | 13 Jahre |
| Grant Hellier Lawrence | M | 63 | 9 Jahre | |
| Per-Olov Eriksson | M | - |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | 21 Jahre |
| Hanne Mette Dyrlie Kristensen | F | - | 3 Jahre | |
| Johan Rasin | M | - |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | 21 Jahre |
| Kjell Gunnarsson | M | - |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | 21 Jahre |
| Johan Dighed | M | 51 |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | - |
| Marianne Kock | F | 69 | 3 Jahre | |
| Graham Eric Fagg | M | 73 |
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | 21 Jahre |
| Achim Kaufhold | M | 66 | 3 Jahre | |
| Jonas Göran Ekblom | M | 59 |
Pergamum AB
 Pergamum AB Pharmaceuticals: MajorHealth Technology Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden. | 14 Jahre |
| Henrik Kristian Moltke | M | 66 | 3 Jahre | |
| Nils-Göran Pettersson | M | 79 |
Pergamum AB
Pergamum AB Pharmaceuticals: MajorHealth Technology Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden. | - |
| Duncan Moore | M | 65 | 8 Jahre | |
| Tine Kold Olesen | M | - | - | |
| Curt Mikael von Euler-Chelpin | M | 71 |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | - |
| Erik Aksel Bork | M | 42 |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | 3 Jahre |
| Dennis Purcell | M | 68 |
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | 7 Jahre |
| Thomas Carbone | M | 67 | 10 Jahre | |
| Fredrik Ahlström | M | - |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | - |
| Raffaele Caldarone | M | - |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | - |
| Enrica Bovina | F | - |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | - |
| Jakob Mosegaard Larsen | M | 52 | 9 Jahre | |
| Karin Birgitta Margareta Ståhl | F | 53 |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | - |
| Jenny Richardson | F | - |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | - |
| Per Blom | M | - |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | - |
| Joakim Notö | M | - |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | - |
| Niels Laursen | M | 68 | - | |
| Claes Lindblad | M | 57 | 3 Jahre | |
| Margit Mahlapuu | M | 52 |
Pergamum AB
Pergamum AB Pharmaceuticals: MajorHealth Technology Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden. | - |
| Nicole Vitullo | F | 66 |
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | 7 Jahre |
| Mattias Klintemar | M | 57 | 3 Jahre | |
| Jonathan Hepple | M | 53 |
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | 23 Jahre |
| Göran Harald Linder | M | 62 |
Pergamum AB
Pergamum AB Pharmaceuticals: MajorHealth Technology Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden. | - |
| Lars Abrahmsén | M | 66 |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | - |
| Michael Perry | M | 64 |
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | 7 Jahre |
| Leila Malik | M | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| J. Buchi | M | 69 | 4 Jahre | |
| Michael Astrue | M | 67 |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | 6 Jahre |
| Joel D. Sendek | M | 57 | 3 Jahre | |
| Michael Midmer | M | - |
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | 9 Jahre |
| Frederick B. Oleson | M | - |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | 5 Jahre |
| John Alam | M | 62 |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | 6 Jahre |
| Jan van de Winkel | M | 63 | 3 Jahre | |
| Morris Z. Rosenberg | M | 64 |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | 8 Jahre |
| Darren Braccia | M | - |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | 2 Jahre |
| Ginette Squires | M | - |
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | - |
| Mark Stejbach | M | 61 |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | 3 Jahre |
| Karen Smith | M | 56 | 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Schweden | 35 | 60,34% |
| Dänemark | 11 | 18,97% |
| Vereinigtes Königreich | 8 | 13,79% |
| Vereinigte Staaten | 6 | 10,34% |
| Norwegen | 1 | 1,72% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Torsten Rüdiger Goesch
- Persönliches Netzwerk
